SWOG clinical trial number
SWOG-8903
Phase I Trial of Promace-CytoBOM with GM-CSF for Treatment of Non-Hodgkin's Lymphoma
Closed
Phase
Accrual
93%
Published
Abbreviated Title
Phase I Trial of Promace-CytoBOM with GM-CSF for Treatment of Non-Hodgkin's Lymphoma
Activated
11/15/1989
Closed
11/01/1993
Research committees
Lymphoma
Publication Information Expand/Collapse
2003
Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate and high grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349)
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/EA4232
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
37%
Open
Phase
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
14%
Open
Phase